Magnetic resonance imaging for improved treatment planning of the prostate

Prostate cancer is the most common malignancy afflicting Canadian men in 2011. Physicians use digital rectal exams (DRE), blood tests for prostate specific antigen (PSA) and transrectal ultrasound (TRUS)-guided biopsies for the initial diagnosis of prostate cancer. None of these tests detail the spa...

Full description

Bibliographic Details
Main Author: Venugopal, Niranjan
Other Authors: McCurdy, Boyd (Physics and Astronomy) Ryner, Lawrence (Physics and Astronomy)
Published: 2012
Subjects:
MRI
TCP
Online Access:http://hdl.handle.net/1993/5071
id ndltd-MANITOBA-oai-mspace.lib.umanitoba.ca-1993-5071
record_format oai_dc
spelling ndltd-MANITOBA-oai-mspace.lib.umanitoba.ca-1993-50712014-01-31T03:32:43Z Magnetic resonance imaging for improved treatment planning of the prostate Venugopal, Niranjan McCurdy, Boyd (Physics and Astronomy) Ryner, Lawrence (Physics and Astronomy) Safi-Harb, Samar (Physics and Astronomy) Lewis, John (Physics and Astronomy) Thomas, Gabriel (Electrical and Computer Engineering) MacKay, Alex (University of British Columbia) Short echo times conformal voxel MRSI LCmodel MRI prostate-cancer lipid-contamination lipid-suppression NTCP TCP histopathology spectroscopy Magnetic resonance imaging Magnetic resonance spectroscopic imaging Prostate cancer is the most common malignancy afflicting Canadian men in 2011. Physicians use digital rectal exams (DRE), blood tests for prostate specific antigen (PSA) and transrectal ultrasound (TRUS)-guided biopsies for the initial diagnosis of prostate cancer. None of these tests detail the spatial extent of prostate cancer - information critical for using new therapies that can target cancerous prostate. With an MRI technique called proton magnetic resonance spectroscopic imaging (1H-MRSI), biochemical analysis of the entire prostate can be done without the need for biopsy, providing detailed information beyond the non-specific changes in hardness felt by an experienced urologist in a DRE, the presence of PSA in blood, or the “blind-guidance” of TRUS-guided biopsy. A hindrance to acquiring high quality 1H-MRSI data comes from signal originating from fatty tissue surrounding prostate that tends to mask or distort signal from within the prostate, thus reducing the overall clinical usefulness of 1H-MRSI data. This thesis has three major areas of focus: 1) The development of an optimized 1H-MRSI technique, called conformal voxel magnetic resonance spectroscopy (CV-MRS), to deal the with removal of unwanted lipid contaminating artifacts at short and long echo times. 2) An in vivo human study to test the CV-MRS technique, including healthy volunteers and cancer patients scheduled for radical prostatectomy or radiation therapy. 3) A study to determine the efficacy of using the 1H-MRSI data for optimized radiation treatment planning using modern delivery techniques like intensity modulated radiation treatment. Data collected from the study using the optimized CV-MRS method show significantly reduced lipid contamination resulting in high quality spectra throughout the prostate. Combining the CV-MRS technique with spectral-spatial excitation further reduced lipid contamination and opened up the possibility of detecting metabolites with short T2 relaxation times. Results from the in vivo study were verified with post-histopathological data. Lastly, 1H-MRSI data was incorporated into the radiation treatment planning software and used to asses tumour control by escalating the radiation to prostate lesions that were identified by 1H-MRSI. In summary, this thesis demonstrates the clinical feasibility of using advanced spectroscopic imaging techniques for improved diagnosis and treatment of prostate cancer. 2012-01-11T18:49:28Z 2012-01-11T18:49:28Z 2012-01-11 http://hdl.handle.net/1993/5071
collection NDLTD
sources NDLTD
topic Short echo times
conformal voxel
MRSI
LCmodel
MRI
prostate-cancer
lipid-contamination
lipid-suppression
NTCP
TCP
histopathology
spectroscopy
Magnetic resonance imaging
Magnetic resonance spectroscopic imaging
spellingShingle Short echo times
conformal voxel
MRSI
LCmodel
MRI
prostate-cancer
lipid-contamination
lipid-suppression
NTCP
TCP
histopathology
spectroscopy
Magnetic resonance imaging
Magnetic resonance spectroscopic imaging
Venugopal, Niranjan
Magnetic resonance imaging for improved treatment planning of the prostate
description Prostate cancer is the most common malignancy afflicting Canadian men in 2011. Physicians use digital rectal exams (DRE), blood tests for prostate specific antigen (PSA) and transrectal ultrasound (TRUS)-guided biopsies for the initial diagnosis of prostate cancer. None of these tests detail the spatial extent of prostate cancer - information critical for using new therapies that can target cancerous prostate. With an MRI technique called proton magnetic resonance spectroscopic imaging (1H-MRSI), biochemical analysis of the entire prostate can be done without the need for biopsy, providing detailed information beyond the non-specific changes in hardness felt by an experienced urologist in a DRE, the presence of PSA in blood, or the “blind-guidance” of TRUS-guided biopsy. A hindrance to acquiring high quality 1H-MRSI data comes from signal originating from fatty tissue surrounding prostate that tends to mask or distort signal from within the prostate, thus reducing the overall clinical usefulness of 1H-MRSI data. This thesis has three major areas of focus: 1) The development of an optimized 1H-MRSI technique, called conformal voxel magnetic resonance spectroscopy (CV-MRS), to deal the with removal of unwanted lipid contaminating artifacts at short and long echo times. 2) An in vivo human study to test the CV-MRS technique, including healthy volunteers and cancer patients scheduled for radical prostatectomy or radiation therapy. 3) A study to determine the efficacy of using the 1H-MRSI data for optimized radiation treatment planning using modern delivery techniques like intensity modulated radiation treatment. Data collected from the study using the optimized CV-MRS method show significantly reduced lipid contamination resulting in high quality spectra throughout the prostate. Combining the CV-MRS technique with spectral-spatial excitation further reduced lipid contamination and opened up the possibility of detecting metabolites with short T2 relaxation times. Results from the in vivo study were verified with post-histopathological data. Lastly, 1H-MRSI data was incorporated into the radiation treatment planning software and used to asses tumour control by escalating the radiation to prostate lesions that were identified by 1H-MRSI. In summary, this thesis demonstrates the clinical feasibility of using advanced spectroscopic imaging techniques for improved diagnosis and treatment of prostate cancer.
author2 McCurdy, Boyd (Physics and Astronomy) Ryner, Lawrence (Physics and Astronomy)
author_facet McCurdy, Boyd (Physics and Astronomy) Ryner, Lawrence (Physics and Astronomy)
Venugopal, Niranjan
author Venugopal, Niranjan
author_sort Venugopal, Niranjan
title Magnetic resonance imaging for improved treatment planning of the prostate
title_short Magnetic resonance imaging for improved treatment planning of the prostate
title_full Magnetic resonance imaging for improved treatment planning of the prostate
title_fullStr Magnetic resonance imaging for improved treatment planning of the prostate
title_full_unstemmed Magnetic resonance imaging for improved treatment planning of the prostate
title_sort magnetic resonance imaging for improved treatment planning of the prostate
publishDate 2012
url http://hdl.handle.net/1993/5071
work_keys_str_mv AT venugopalniranjan magneticresonanceimagingforimprovedtreatmentplanningoftheprostate
_version_ 1716629102898708480